Results of Chemotherapy of Malignant Brain Tumors in Adults

Krauseneck, P.; Mertens, H. G.

doi:10.1007/978-3-7091-8876-7_7

Cited by 11 publications

(4 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings need to be pursued in the phase Ill study, utilizing a concurrent control group. There are currently several studies showing improved ST in malignant glioma patients who are receiving a combination of different chemotherapeutic agents and radiotherapy after surgery [20]. In conclusion this study demonstrates that the combination of CDDP + VPt6 is effective in patients with malignant gliomas and may be beneficial as adjuvant chemotherapy in some patients, as well considering the number of surviving patients after the 18th month post surgery.…”

Section: Discussionmentioning

confidence: 81%

“…In a recent review of phase II and III trials, Kornblith [17] noted that many of these studies were reported as showing some advantage for the multidrug regimen over control series utilizing radiotherapy alone after surgery. Among the reported studies, in primary malignant gliomas after surgery and radiotherapy associated with supportive chemotherapy with nitrosoureas, given alone or in association with other drugs, it is interesting to note that the TTP was reported as 31 and 29 weeks [18,19], as 32 weeks [20] and as 39 weeks in a trial (EORTC group 83) in which however all cases were not GBM [14]. Unfortunately the trials are often not comparable because differently graded gliomas are mixed in the same list of patients.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Primary glial tumor patients treated by combining cis-platin and etoposide

et al. 1991

View full text Add to dashboard Cite

Thirty eight patients with malignant gliomas (27 GBM and 11 AA) were treated with up to 7 cycles of CDDP + VP16 every month after surgery. Chemotherapy was planned as two cycles before and 5 cycles after radiation (42 Gy) using a three times daily fractionation schedule. No severe toxicity was observed. The object of our study was to investigate the antitumor effectiveness by combining CDDP plus VP16 against primary malignant glial tumors. The time to tumor progression (TTP) and survival time (ST) of the GBM patients in the present study were 38.5 and 68.5 weeks respectively. The TTP of the AA patients was 73 weeks and the ST was not calculated as most patients are still alive. By the 18th. month after surgery, 38% of GBM and 74% of AA patients treated with (CDDP + VP16) are still alive. This study demonstrates that the combination of CDDP and VP16 is effective in patients with malignant gliomas.

show abstract

Section: Discussionmentioning

confidence: 81%

Section: Discussionmentioning

confidence: 98%

Primary glial tumor patients treated by combining cis-platin and etoposide

et al. 1991

View full text Add to dashboard Cite

show abstract

“…In a late review of phase II and III trials Kornblith [12] noted that many of these studies were reported as showing some advantage for the multidrug regimen over control series utilizing radiotherapy alone after surgery. The TrP in AA patients was 63,7 weeks, according to published data [13]. Unfortunately the trials are often not comparable because differently graded gliomas are mixed in the same list.…”

Section: Discussionmentioning

confidence: 99%

“…The present study shows that the combination of cisplatin and VP-16 may be effective against malignant glial tumors. Needless to say one year is the MST for GBM reported in the literature [13]. This regimen of chemotherapy could induce stabilization of disease in a high percentage of glioma patients; actually only one out of 5 patients failed to respond to this drug combination.…”

Section: Discussionmentioning

confidence: 99%